The Therascreen PITX2 RGQ PCR kit (Qiagen, Germany) is a methylation-based CE-IVD marked assay that predicts the response of lymph node-positive, ER-positive, and HER2-negative high-risk breast cancer patients. Here, ERBB2 is linked to breast carcinoma.